Pfizer's Xeljanz elected in US as 1st JAK in RA
This article was originally published in Scrip
Executive Summary
The US FDA on 6 November sanctioned pharma giant Pfizer's Xeljanz (tofacitinib citrate) as a treatment for adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or are intolerant to methotrexate – granting the approval two weeks ahead of the medicine's action goal date.
You may also be interested in...
AbbVie’s Rinvoq Delay By US FDA Could Foreshadow More Trouble For JAKs
The expansion of upadacitinib for a new indication in psoriatic arthritis has been pushed out three months to late in the second quarter.
First Phase III Results Keep Pfizer's Abrocitinib Among JAK Leaders In Atopic Dermatitis
Pfizer follows Lilly as the second company to report positive top-line Phase III results in AD for a JAK inhibitor. Safety is a key concern for the class, but Pfizer did not provide any details about abrocitinib's side effects.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.